<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200093</url>
  </required_header>
  <id_info>
    <org_study_id>CIC 1745-B-17 Laguio-Vila</org_study_id>
    <nct_id>NCT03200093</nct_id>
  </id_info>
  <brief_title>Oral Vancomycin for Preventing Clostridium Difficile Recurrence</brief_title>
  <official_title>Secondary Prophylaxis With Oral Vancomycin for Clostridium Difficile Recurrence: A Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rochester General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rochester General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium
      difficile for hospitalized patients receiving systemic antibiotic therapy. Half of
      participants will receive oral vancomycin daily, while the other half will receive a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clostridium difficile colitis is a significant cause of morbidity and mortality among
      hospitalized patients. Following the first episode, up to 15% of people experience recurrent
      disease. A major risk factor for recurrent disease is exposure to systemic antibiotics.

      Oral vancomycin given four times daily is one of the treatments for Clostridium difficile
      infection; it is not known if giving oral vancomycin at a lower dose such as once daily may
      help prevent recurrences. Oral vancomycin may be most helpful in preventing recurrences when
      given to patients at greatest risk of recurrent disease, such as when they are receiving
      systemic antibiotics.

      To evaluate this, the investigators propose comparing the rates of recurrent Clostridium
      difficile infection in patients who receive oral vancomycin with systemic antibiotics to when
      patients take systemic antibiotics alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>After enrollment, study pharmacists will randomize the participants to receive either oral vancomycin or placebo. Participants, care providers, investigators, and outcomes assessors will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>30-day recurrent Clostridium difficile infection</measure>
    <time_frame>30 days</time_frame>
    <description>A positive Clostridium difficile stool test in the 30 days following completion of the systemic antibiotic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90-day recurrent Clostridium difficile infection</measure>
    <time_frame>90 days</time_frame>
    <description>A positive Clostridium difficile stool test in the 90 days following completion of the systemic antibiotic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day hospital re-admission</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause re-admission to any hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality in the 30 days following completion of the systemic antibiotics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of duration of systemic antibiotics on Clostridium difficile recurrence</measure>
    <time_frame>90 days</time_frame>
    <description>Comparing the frequency of a positive Clostridium difficile stool test in the 90 days following completion of systemic antibiotics, when the duration of systemic antibiotics was less than or equal to 14 days compared to longer durations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of acid-suppressing medications on Clostridium difficile recurrence</measure>
    <time_frame>90 days</time_frame>
    <description>Comparing the frequency of a positive Clostridium difficile stool test in the 90 days following completion of systemic antibiotics, when the participant was receiving acid-suppressing medications compared to those on none.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of age on Clostridium difficile recurrence</measure>
    <time_frame>90 days</time_frame>
    <description>Comparing the frequency of a positive Clostridium difficile stool test in the 90 days following completion of systemic antibiotics, when the participant was older than 65 years of age compared to younger.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of systemic antibiotic class on Clostridium difficile recurrence</measure>
    <time_frame>90 days</time_frame>
    <description>Comparing the frequency of a positive Clostridium difficile stool test in the 90 days following completion of systemic antibiotics, when the participant was receiving systemic antibiotics considered &quot;high risk&quot; for Clostridium difficile compared to those taking &quot;low risk&quot; antibiotics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vancomycin resistance isolated</measure>
    <time_frame>90 days</time_frame>
    <description>Isolation of a vancomycin-resistant bacteria during an infectious workup, if clinically indicated</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Oral vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.
Taken by mouth once daily for:
If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.
If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ora-Sweet 5 mL
Taken by mouth once daily for:
If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.
If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Vancomycin</intervention_name>
    <description>Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.</description>
    <arm_group_label>Oral vancomycin</arm_group_label>
    <other_name>Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ora-Sweet 5mL taken by mouth once daily.</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>Study placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older

          -  A history of Clostridium difficile infection based on a positive Clostridium difficile
             stool test performed at a lab affiliated with Rochester Regional Health System in the
             12 months prior to enrollment

          -  A new in-patient admission, with an antibiotic treatment plan for greater than 48
             hours

        Exclusion Criteria:

          -  Documented allergy and/or adverse drug reaction to vancomycin

          -  Pregnant

          -  Patients who are admitted with a current episode of Clostridium difficile infection

          -  Patients with total colectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maryrose R Laguio-Vila, MD</last_name>
    <phone>5859224003</phone>
    <email>maryrose.laguiovila@rochesterregional.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Staicu, PharmD</last_name>
    <phone>5859225732</phone>
    <email>mary.staicu@rochesterregional.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryrose R Laguio-Vila, MD</last_name>
      <phone>585-922-4003</phone>
      <email>maryrose.laguiovila@rochesterregional.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Staicu, PharmD</last_name>
      <phone>5859225732</phone>
      <email>mary.staicu@rochesterregional.org</email>
    </contact_backup>
    <investigator>
      <last_name>Youssef Soliman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siddhant Datta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohit Ramachandran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Lourdes Brundige, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Bress, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.</citation>
    <PMID>25714160</PMID>
  </reference>
  <reference>
    <citation>Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26. Review.</citation>
    <PMID>23439232</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014 Mar 17;7:63-72. doi: 10.2147/IDR.S46780. eCollection 2014. Review.</citation>
    <PMID>24669194</PMID>
  </reference>
  <reference>
    <citation>Vincent C, Manges AR. Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection. Antibiotics (Basel). 2015 Jul 3;4(3):230-53. doi: 10.3390/antibiotics4030230. Review.</citation>
    <PMID>27025623</PMID>
  </reference>
  <reference>
    <citation>Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012 Jul;107(7):1079-87. doi: 10.1038/ajg.2012.60. Epub 2012 Mar 27.</citation>
    <PMID>22450732</PMID>
  </reference>
  <reference>
    <citation>van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.</citation>
    <PMID>23323867</PMID>
  </reference>
  <reference>
    <citation>Carignan A, Poulin S, Martin P, Labbé AC, Valiquette L, Al-Bachari H, Montpetit LP, Pépin J. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections. Am J Gastroenterol. 2016 Dec;111(12):1834-1840. doi: 10.1038/ajg.2016.417. Epub 2016 Sep 13.</citation>
    <PMID>27619835</PMID>
  </reference>
  <reference>
    <citation>Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents. Clin Infect Dis. 2016 Sep 1;63(5):651-3. doi: 10.1093/cid/ciw401. Epub 2016 Jun 17.</citation>
    <PMID>27318333</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rochester General Hospital</investigator_affiliation>
    <investigator_full_name>Maryrose R Laguio-Vila</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>C diff</keyword>
  <keyword>Oral Vancomycin</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

